ACIU AC Immune SA

7.24
-0.27  -4%
Previous Close 7.51
Open 7.52
Price To Book 1.85
Market Cap 520,262,280
Shares 71,859,431
Volume 175,615
Short Ratio
Av. Daily Volume 166,001
Stock charts supplied by TradingView

NewsSee all news

  1. AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases

    Seven presentations by AC Immune and its partners at AAT-AD/PD™ New data on early-stage TDP-43 and alpha-synuclein therapeutic and diagnostic candidates  A lead anti-alpha-synuclein therapeutic antibody candidate

  2. AC Immune Reports Full-Year 2019 Financial Results and Provides 2020 R&D Outlook

    Ongoing strong financial position with CHF 288.6 million in cash, ensuring the Company is fully financed through Q1 2024, excluding potential incoming milestonesReceived CHF 110 million in upfront and development

  3. AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

    CHF 10 million milestone recognizes development progressUpdated financial terms add a new CHF 60 million milestone for Phase 2 initiationTotal potential deal value is now CHF 1.86 billion, up from CHF 1.82 billion

  4. AC Immune to Present New Data Demonstrating the Depth of its Neurodegenerative Programs at the Upcoming Advances in Alzheimer's and Parkinson's Therapies Focus Meeting

    LAUSANNE, Switzerland, March 05, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company, announced today that four new data presentations will be delivered at this

  5. AC Immune to Present at Jefferies 2019 London Healthcare Conference

    LAUSANNE, Switzerland, Nov. 14, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today announced

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 2
Alzheimer’s disease
Phase 2 primary completion 2Q 2020.
RG6100 (Anti-Tau RO7105705)
Alzheimer’s disease
Phase 1/2 interim data released July 2019.
ACI-24 (anti-Abeta vaccine)
Alzheimer's disease-like characteristics in individuals with Down syndrome
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 1
Alzheimer’s disease
Phase 2 trial initiation announced February 20, 2019.
MTAU9937A
Alzheimer’s disease
Phase 2 trial planned for 1H 2019.
ACI-35
Alzheimer’s disease
Phase 1 data due 2H 2020.
ACI-3024
Alzheimer’s disease
Phase 1b/2 interim analysis 2Q 2020.
ACI-35.030
Alzheimer’s Disease
Phase 2 12-month analysis due 2H 2020.
ACI-24
Alzheimer’s disease (AD)

Latest News

  1. AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases

    Seven presentations by AC Immune and its partners at AAT-AD/PD™ New data on early-stage TDP-43 and alpha-synuclein therapeutic and diagnostic candidates  A lead anti-alpha-synuclein therapeutic antibody candidate

  2. AC Immune Reports Full-Year 2019 Financial Results and Provides 2020 R&D Outlook

    Ongoing strong financial position with CHF 288.6 million in cash, ensuring the Company is fully financed through Q1 2024, excluding potential incoming milestonesReceived CHF 110 million in upfront and development

  3. AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

    CHF 10 million milestone recognizes development progressUpdated financial terms add a new CHF 60 million milestone for Phase 2 initiationTotal potential deal value is now CHF 1.86 billion, up from CHF 1.82 billion

  4. AC Immune to Present New Data Demonstrating the Depth of its Neurodegenerative Programs at the Upcoming Advances in Alzheimer's and Parkinson's Therapies Focus Meeting

    LAUSANNE, Switzerland, March 05, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company, announced today that four new data presentations will be delivered at this

  5. AC Immune to Present at Jefferies 2019 London Healthcare Conference

    LAUSANNE, Switzerland, Nov. 14, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today announced

  6. AC Immune Q3 2019 Financial Results and Business Update

     CHF 32 Million in Milestone Revenues Multiple Upcoming Catalysts Execution Across Clinical and Preclinical Neurodegenerative Development Pipeline LAUSANNE, Switzerland, Nov. 13, 2019 (GLOBE NEWSWIRE) -- AC

  7. AC Immune Hosts Key Opinion Leader Event: 'Untangling' Tau Pathology to Treat Alzheimer's and Neurodegenerative Diseases

    Company Provides Key Updates on Tau Pipeline Candidates LAUSANNE, Switzerland, Nov. 06, 2019 (GLOBE NEWSWIRE) --  AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad

  8. AC Immune to Host Key Opinion Leader Event: 'Untangling' Tau Pathology to Treat Alzheimer's and Neurodegenerative Diseases

    LAUSANNE, Switzerland, Oct. 24, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced

  9. AC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer™ Program

    Lilly to pay CHF30 million development milestone Recognizes progress in ACI-3024 Small Molecule Tau Morphomer™ development LAUSANNE, Switzerland, Sept. 20, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a

  10. AC Immune Receives Milestone Payment in Connection with Initiation of a Phase 2 Trial of Tau PET Tracer PI-2620

    Next generation Tau tracer offers potential for earlier and more accurate diagnosis in Alzheimer's and neurodegenerative diseases The clinical milestone highlights the strength of AC Immune's Tau pipeline, one of the

  11. AC Immune Awarded Michael J. Fox Foundation Grant to Accelerate Development of Parkinson's Disease Diagnostic Imaging Agent

    LAUSANNE, Switzerland, Sept. 04, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced